Exploring The FDA's Draft Guidance On Psychedelic Drug Research

The FDA recently published a first-ever draft guidance on clinical development requirements for psychedelic drugs.

Join Altasciences’ panel of experts as they provide an in-depth review of the guidance and valuable insights into the areas where further methodological adaptations to study designs may be necessary. These adaptations play a pivotal role in accurately assessing the safety, pharmacology, and efficacy of groundbreaking psychedelic compounds developed for specific medical applications.

Altasciences is a progressive, medium-sized contract research organization that provides pharmaceutical and biotechnology companies with a well-established and adaptable approach to preclinical and clinical pharmacology studies. Their services encompass formulation, manufacturing, and analytical services, demonstrating their commitment to excellence in the industry.